Sublicensee Revenue. ACCENTIA shall pay to BDSI either: (i) an amount equal to fifty percent (50%) of Sublicensee Revenue to BDSI, after the prescribed royalty payment to MAYO; or (ii) a minimum royalty of eight percent (8%) of Sublicensee Net Sales (regardless of the prescribed royalty to MAYO), whichever is greater, for Licensed Products.
Appears in 4 contracts
Samples: License Agreement (Accentia Biopharmaceuticals Inc), License Agreement (Accentia Biopharmaceuticals Inc), License Agreement (Accentia Biopharmaceuticals Inc)
